Top

Published in:

Open Access 01-12-2024 | Research

Effectiveness of gold nanoparticles in prevention and treatment of oral mucositis in animal models: a systematic review

Authors: Minati Choudhury, Paul Brunton, Donald Schwass, Daniel Pletzer, Jithendra Ratnayake, George Dias, Geoffrey Tompkins

Published in: Systematic Reviews | Issue 1/2024

Abstract

Background

Oral mucositis remains a significant complication during cancer therapy with no effective treatment. Gold nanoparticles offer anti-inflammatory, antioxidant properties with low toxicity. This study systematically reviews the literature assessing gold nanoparticles in the management of oral mucositis in animal models.

Methods

A literature search was undertaken using MEDLINE, Embase, PubMed, and Web of Science databases, using the format for Systematic Review Centre for Laboratory Animal Experimentation. Prior to the review, the protocol was registered in the systematic review register, PROSPERO (registration no. CRD42021272169). Outcome measures included ulceration, histopathological scores, inflammatory mediators, microbial growth, and pain. Study quality was analysed by SYRCLE risk-of-bias tool.

Results

Only one study met the inclusion criteria, documenting reduction in ulceration, inflammatory, and oxidative biomarkers. Exposure to AuNPs prevented inflammatory response induced by 5-fluorouracil in oral mucosa of hamsters. However, a high risk of bias necessitates further research.

Conclusion

This review identifies a potential therapeutic strategy for prevention and management of oral mucositis. It also provides future direction for gold nanoparticle research in oral mucositis; however, there is lack of sufficient evidence to derive any conclusion. Research with standardized parameters including nanoparticle size, capping agent, surface charge, and appropriate oral mucositis animal models will establish risk–benefit balance and margin of safety for therapeutic use of gold nanoparticles for oral mucositis.

Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003;66(3):253–62.PubMedCrossRef

Bowen J, Al-Dasooqi N, Bossi P, Wardill H, Van Sebille Y, Al-Azri A, et al. The pathogenesis of mucositis: updated perspectives and emerging targets. Support Care Cancer. 2019;27(10):4023–33.PubMedCrossRef

Elting LS, Cooksley CD, Chambers MS, Garden AS. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007;68(4):1110–20.PubMedCrossRef

Sonis ST. New thoughts on the initiation of mucositis. Oral Dis. 2010;16(7):597–600.PubMedCrossRef

Sonis ST. A biological approach to mucositis. J Support Oncol. 2004;2(1):21–32 discussion 5-6.PubMed

Liu T, Zhang L, Joo D, Sun S-C. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023.PubMedPubMedCentralCrossRef

Sonis ST. The biologic role for nuclear factor-kappaB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med. 2002;13(5):380–9.PubMedCrossRef

Logan RM, Gibson RJ, Sonis ST, Keefe DM. Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol. 2007;43(4):395–401.PubMedCrossRef

Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther. 2008;7(7):1139–45.PubMedCrossRef

10.

Sonis ST, O’Donnell KE, Popat R, Bragdon C, Phelan S, Cocks D, et al. The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol. 2004;40(2):170–6.PubMedCrossRef

11.

Khan MA, Khan MJ. Nano-gold displayed anti-inflammatory property via NF-kB pathways by suppressing COX-2 activity. Artif Cells Nanomed Biotechnol. 2018;46(sup1):1149–58.PubMedCrossRef

12.

Reyes-Gibby CC, Wang J, Zhang L, Peterson CB, Do KA, Jenq RR, et al. Oral microbiome and onset of oral mucositis in patients with squamous cell carcinoma of the head and neck. Cancer. 2020;126(23):5124–36.PubMedCrossRef

13.

Wei L, Wen XS, Xian CJ. Chemotherapy-induced intestinal microbiota dysbiosis impairs mucosal homeostasis by modulating toll-like receptor signaling pathways. Int J Mol Sci. 2021;22(17):9474.PubMedPubMedCentralCrossRef

14.

Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4(4):277–84.PubMedCrossRef

15.

Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126(19):4423–31.PubMedCrossRef

16.

Blakaj A, Bonomi M, Gamez ME, Blakaj DM. Oral mucositis in head and neck cancer: evidence-based management and review of clinical trial data. Oral Oncol. 2019;95:29–34.PubMedCrossRef

17.

Elad S. The MASCC/ISOO Mucositis Guidelines 2019 Update: introduction to the first set of articles. Support Care Cancer. 2019;27(10):3929–31.PubMedCrossRef

18.

Yarom N, Hovan A, Bossi P, Ariyawardana A, Jensen SB, Gobbo M, et al. Systematic review of natural and miscellaneous agents for the management of oral mucositis in cancer patients and clinical practice guidelines—part 1: vitamins, minerals, and nutritional supplements. Support Care Cancer. 2019;27(10):3997–4010.PubMedCrossRef

19.

Ala M, Mohammad Jafari R, Ala M, Agbele AT, Hejazi SM, Tavangar SM, et al. Sumatriptan alleviates radiation-induced oral mucositis in rats by inhibition of NF-kB and ERK activation, prevention of TNF-α and ROS release. Arch Oral Biol. 2020;119:104919.PubMedCrossRef

20.

Araújo A, Varela H, de Medeiros CAC, Brito G, Lima K, Moura L, et al. Azilsartan reduced TNF-α and IL-1β levels, increased IL-10 levels and upregulated VEGF, FGF, KGF, and TGF-α in an oral mucositis model. PLoS One. 2015;10:e0116799.PubMedPubMedCentralCrossRef

21.

Xiao H, Fan Y, Li Y, Dong J, Zhang S, Wang B, et al. Oral microbiota transplantation fights against head and neck radiotherapy-induced oral mucositis in mice. Comput Struct Biotechnol J. 2021;19:5898–910.PubMedPubMedCentralCrossRef

22.

Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 2005;1(3):325–7.PubMedCrossRef

23.

Sumbayev VV, Yasinska IM, Garcia CP, Gilliland D, Lall GS, Gibbs BF, et al. Gold nanoparticles downregulate interleukin-1β-induced pro-inflammatory responses. Small. 2013;9(3):472–7.PubMedCrossRef

24.

Zhu S, Jiang X, Boudreau MD, Feng G, Miao Y, Dong S, et al. Orally administered gold nanoparticles protect against colitis by attenuating toll-like receptor 4- and reactive oxygen/nitrogen species-mediated inflammatory responses but could induce gut dysbiosis in mice. J Nanobiotechnology. 2018;16(1):86.PubMedPubMedCentralCrossRef

25.

Leonaviciene L, Kirdaite G, Bradunaite R, Vaitkiene D, Vasiliauskas A, Zabulyte D, et al. Effect of gold nanoparticles in the treatment of established collagen arthritis in rats. Med Lith. 2012;48(2):91–101.

26.

Ko WC, Shieh JM, Wu WB. P38 MAPK and Nrf2 activation mediated naked gold nanoparticle induced heme oxygenase-1 expression in rat aortic vascular smooth muscle cells. Arch Med Res. 2020;51(5):388–96.PubMedCrossRef

27.

Saleh H, Salama M, Hussein RM. Polyethylene glycol capped gold nanoparticles ameliorate renal ischemia–reperfusion injury in diabetic mice through AMPK-Nrf2 signaling pathway. Environ Sci Pollut Res. 2022;29(51):77884–907.CrossRef

28.

Nguyen H, Sangha S, Pan M, Shin DH, Park H, Mohammed AI, et al. Oxidative stress and chemoradiation-induced oral mucositis: a scoping review of in vitro, in vivo and clinical studies. Int J Mol Sci. 2022;23(9):4863.PubMedPubMedCentralCrossRef

29.

Vilar CJF, Ribeiro SB, de Araújo AA, Guerra GCB, de AraújoJúnior RF, Brito GAdC, et al. Effect of gold nanoparticle on 5-fluorouracil-induced experimental oral mucositis in hamsters. Pharmaceutics. 2020;12(4):304.PubMedPubMedCentralCrossRef

30.

Coradeghini R, Gioria S, Garcia CP, Nativo P, Franchini F, Gilliland D, et al. Size-dependent toxicity and cell interaction mechanisms of gold nanoparticles on mouse fibroblasts. Toxicol Lett. 2013;217(3):205–16.PubMedCrossRef

31.

Huang KY, Ma HL, Liu J, Huo SD, Kumar A, Wei T, et al. Size-Dependent localization and penetration of ultrasmall gold nanoparticles in cancer cells, multicellular spheroids, and tumors in vivo. ACS Nano. 2012;6(5):4483–93.PubMedPubMedCentralCrossRef

32.

Kim K-T, Zaikova T, Hutchison JE, Tanguay RL. Gold nanoparticles disrupt zebrafish eye development and pigmentation. Toxicol Sci. 2013;133(2):275–88.PubMedPubMedCentralCrossRef

33.

Feng ZV, Gunsolus IL, Qiu TA, Hurley KR, Nyberg LH, Frew H, et al. Impacts of gold nanoparticle charge and ligand type on surface binding and toxicity to gram-negative and gram-positive bacteria. Chem Sci. 2015;6(9):5186–96.PubMedPubMedCentralCrossRef

34.

Fraga S, Faria H, Soares ME, Duarte JA, Soares L, Pereira E, et al. Influence of the surface coating on the cytotoxicity, genotoxicity and uptake of gold nanoparticles in human HepG2 cells. J Appl Toxicol. 2013;33(10):1111–9.PubMedCrossRef

35.

Goodman CM, McCusker CD, Yilmaz T, Rotello VM. Toxicity of gold nanoparticles functionalized with cationic and anionic side chains. Bioconjugate Chem. 2004;15(4):897–900.CrossRef

36.

McGuire DB, Fulton JS, Park J, Brown CG, Correa ME, Eilers J, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(11):3165–77.PubMedCrossRef

37.

Migliorati C, Hewson I, Lalla RV, Antunes HS, Estilo CL, Hodgson B, et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(1):333–41.PubMedCrossRef

38.

Nicolatou-Galitis O, Sarri T, Bowen J, Di Palma M, Kouloulias VE, Niscola P, et al. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(11):3179–89.PubMedCrossRef

39.

Nicolatou-Galitis O, Sarri T, Bowen J, Di Palma M, Kouloulias VE, Niscola P, et al. Systematic review of amifostine for the management of oral mucositis in cancer patients. Support Care Cancer. 2013;21(1):357–64.PubMedCrossRef

40.

Ritskes-Hoitinga M, van Luijk J. How can systematic reviews teach us more about the implementation of the 3Rs and animal welfare? Animals. 2019;9(12):1163.PubMedPubMedCentralCrossRef

41.

Horn J, de Haan RJ, Vermeulen M, Luiten PGM, Limburg M. Nimodipine in animal model experiments of focal cerebral ischemia. Stroke. 2001;32(10):2433–8.PubMedCrossRef

42.

Panghal M, Kaushal V, Kadayan S, Yadav JP. Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocols. BMC Oral Health. 2012;12(1):22.PubMedPubMedCentralCrossRef

43.

Perez P, Patiño J, Estacio M, Pino J, Manzi E, Medina D. Bacteremia in pediatric patients with hematopoietic stem cell transplantation. Hematol Transfus Cell Ther. 2020;42(1):5–11.PubMedCrossRef

44.

de Vries RBM, Hooijmans CR, Langendam MW, van Luijk J, Leenaars M, Ritskes-Hoitinga M, et al. A protocol format for the preparation, registration and publication of systematic reviews of animal intervention studies. Evid Based Preclin Med. 2015;2(1):e00007.CrossRef

45.

Leenaars M, Hooijmans CR, van Veggel N, ter Riet G, Leeflang M, Hooft L, et al. A step-by-step guide to systematically identify all relevant animal studies. Lab Anim. 2012;46(1):24–31.PubMedPubMedCentralCrossRef

46.

Zhang S-K, Zheng R, Chen Q, Zhang S, Sun X, Chen W. Oral cancer incidence and mortality in China, 2011. Chin J Cancer Res. 2015;27(1):44–51.PubMedPubMedCentralCrossRef

47.

Pizzorno J. Glutathione! Integr Med (Encinitas). 2014;13(1):8–12.PubMed

48.

Cardona A, Balouch A, Abdul MM, Sedghizadeh PP, Enciso R. Efficacy of chlorhexidine for the prevention and treatment of oral mucositis in cancer patients: a systematic review with meta-analyses. J Oral Pathol Med. 2017;46(9):680–8.PubMedCrossRef

49.

Curra M, Pellicioli AC, Filho NA, Ochs G, Matte Ú, Filho MS, et al. Photobiomodulation reduces oral mucositis by modulating NF-kB. J Biomed Opt. 2015;20(12):125008.PubMedCrossRef

50.

Lalla RV, Choquette LE, Curley KF, Dowsett RJ, Feinn RS, Hegde UP, et al. Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer. Oral Oncol. 2014;50(11):1098–103.PubMedPubMedCentralCrossRef

51.

Oton-Leite AF, Silva GB, Morais MO, Silva TA, Leles CR, Valadares MC, et al. Effect of low-level laser therapy on chemoradiotherapy-induced oral mucositis and salivary inflammatory mediators in head and neck cancer patients. Lasers Surg Med. 2015;47(4):296–305.PubMedCrossRef

52.

Ribeiro SB, de Araújo AA, Oliveira MMB, Santos Silva AMD, da Silva-Júnior AA, Guerra GCB, et al. Effect of dexamethasone-loaded PLGA nanoparticles on oral mucositis induced by 5-fluorouracil. Pharmaceutics. 2021;13(1):53.PubMedPubMedCentralCrossRef

53.

Wang L, Gu Z, Zhai R, Zhao S, Luo L, Li D, et al. Efficacy of oral cryotherapy on oral mucositis prevention in patients with hematological malignancies undergoing hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. PLoS One. 2015;10(5):e0128763.PubMedPubMedCentralCrossRef

54.

Huang Y-J, Shiau A-L, Chen S-Y, Chen Y-L, Wang C-R, Tsai C-Y, et al. Multivalent structure of galectin-1-nanogold complex serves as potential therapeutics for rheumatoid arthritis by enhancing receptor clustering. Eur Cell Mater. 2012;23:170–81.PubMedCrossRef

55.

Tsai CY, Shiau AL, Chen SY, Chen YH, Cheng PC, Chang MY, et al. Amelioration of collagen-induced arthritis in rats by nanogold. Arthritis Rheum. 2007;56(2):544–54.PubMedCrossRef

56.

Ali SG, Ansari MA, Alzohairy MA, Alomary MN, AlYahya S, Jalal M, et al. Biogenic gold nanoparticles as potent antibacterial and antibiofilm nano-antibiotics against Pseudomonas aeruginosa. Antibiotics (Basel). 2020;9(3):100.PubMedCrossRef

57.

Giri K, Rivas Yepes L, Duncan B, Kolumam Parameswaran P, Yan B, Jiang Y, et al. Targeting bacterial biofilms via surface engineering of gold nanoparticles. RSC Adv. 2015;5(128):105551–9.PubMedCrossRef

58.

Yu Q, Li J, Zhang Y, Wang Y, Liu L, Li M. Inhibition of gold nanoparticles (AuNPs) on pathogenic biofilm formation and invasion to host cells. Sci Rep. 2016;6(1):26667.PubMedPubMedCentralCrossRef

59.

Lebedová J, Hedberg YS, Odnevall Wallinder I, Karlsson HL. Size-dependent genotoxicity of silver, gold and platinum nanoparticles studied using the mini-gel comet assay and micronucleus scoring with flow cytometry. Mutagenesis. 2017;33(1):77–85.CrossRef

60.

Senut M-C, Zhang Y, Liu F, Sen A, Ruden DM, Mao G. Size-dependent toxicity of gold nanoparticles on human embryonic stem cells and their neural derivatives. Small. 2016;12(5):631–46.PubMedCrossRef

61.

Simpson CA, Salleng KJ, Cliffel DE, Feldheim DL. In vivo toxicity, biodistribution, and clearance of glutathione-coated gold nanoparticles. Nanomedicine Nanotechnol Biolo Med. 2013;9(2):257–63.CrossRef

62.

Yaffe J, Montgomery P, Hopewell S, Shepard LD. Empty reviews: a description and consideration of Cochrane Systematic Reviews with No Included Studies. PLoS One. 2012;7(5):e36626.PubMedPubMedCentralCrossRef

63.

Laprise-Pelletier M, Simão T, Fortin M-A. Gold nanoparticles in radiotherapy and recent progress in nanobrachytherapy. Adv Healthcare Mater. 2018;7(16):1701460.CrossRef

64.

Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14:43.PubMedPubMedCentralCrossRef

65.

Charan J, Kantharia ND. How to calculate sample size in animal studies? J Pharmacol Pharmacother. 2013;4(4):303–6.PubMedPubMedCentralCrossRef

66.

Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.PubMedPubMedCentralCrossRef

67.

Smith AJ, Clutton RE, Lilley E, Hansen KEA, Brattelid T. Improving animal research: PREPARE before you ARRIVE. BMJ. 2018;360:k760.PubMedCrossRef

Title: Effectiveness of gold nanoparticles in prevention and treatment of oral mucositis in animal models: a systematic review
Authors: Minati Choudhury
Paul Brunton
Donald Schwass
Daniel Pletzer
Jithendra Ratnayake
George Dias
Geoffrey Tompkins
Publication date: 01-12-2024
Publisher: BioMed Central
Published in: Systematic Reviews / Issue 1/2024
Electronic ISSN: 2046-4053
DOI: https://doi.org/10.1186/s13643-023-02425-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Effectiveness of gold nanoparticles in prevention and treatment of oral mucositis in animal models: a systematic review

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2024

The effect of acupuncture on oxidative stress in animal models of vascular dementia: a systematic review and meta-analysis

The effectiveness of short mobile phone text message reminders compared to usual care on medication adherence in patients with hypertension: a systematic review protocol

Assessing risk of bias in the meta-analysis of round 1 of the Health Care Innovation Awards

Prevalence of thyroid dysfunction and associated factors among adult type 2 diabetes mellitus patients, 2000–2022: a systematic review and meta-analysis

Safety and efficacy of intravenous thrombolysis before mechanical thrombectomy in patients with atrial fibrillation

Online dissemination of Cochrane reviews on digital health technologies: a cross-sectional study